BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oosenbrug T, van den Wollenberg DJM, Duits EW, Hoeben RC, Ressing ME. Induction of Robust Type I Interferon Levels by Oncolytic Reovirus Requires Both Viral Replication and Interferon-α/β Receptor Signaling. Hum Gene Ther 2021;32:1171-85. [PMID: 34405701 DOI: 10.1089/hum.2021.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiong F, Wang Q, Wu G, Liu W, Wang B, Chen Y. Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow. Biomark Res 2022;10. [DOI: 10.1186/s40364-022-00415-y] [Reference Citation Analysis]
2 Li Q, Tan F, Wang Y, Liu X, Kong X, Meng J, Yang L, Cen S. The gamble between oncolytic virus therapy and IFN. Front Immunol 2022;13:971674. [DOI: 10.3389/fimmu.2022.971674] [Reference Citation Analysis]
3 Song J, Li M, Li C, Liu K, Zhu Y, Zhang H. Friend or foe: RIG- I like receptors and diseases. Autoimmun Rev 2022;:103161. [PMID: 35926770 DOI: 10.1016/j.autrev.2022.103161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bakacs T, Safadi R, Puskás LG, Fehér LZ, Kovesdi I. Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality. Cureus 2022. [DOI: 10.7759/cureus.22750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]